Literature DB >> 16212142

Chronic nitrofurantoin-induced lung disease.

Jose L Mendez1, Hassan F Nadrous, Thomas E Hartman, Jay H Ryu.   

Abstract

OBJECTIVE: To reassess the clinical and radiological features of chronic nitrofurantoin-induced lung disease and eventual clinical outcome. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 18 patients with chronic nitrofurantoin-induced lung disease who were seen at the Mayo Clinic in Rochester, Minn, from January 1, 1997, to December 31, 2002.
RESULTS: The median age of the 18 patients was 72 years (range, 47-90 years) at the time of diagnosis; 17 (94%) were women. Onset of symptoms occurred after a median interval of 23 months (range, 10-144 months) following the initiation of nitrofurantoin therapy for the prevention of recurrent urinary tract infections. All patients presented with persistent dyspnea and cough associated with lung infiltrates detected on chest radiography. Ten computed tomograms were available for review and revealed bilateral areas of ground-glass opacities in all cases and showed subpleural Irregular linear opacities and patchy consolidation in some cases. Nitrofurantoin therapy was discontinued in all patients, and most improved subsequently; 9 patients received corticosteroid therapy.
CONCLUSIONS: Chronic nitrofurantoin-induced lung disease is seen predominantly in older women who present with respiratory symptoms after a year or more of nitrofurantoin therapy. Associated radiological features are relatively nonspecific but usually include bilateral areas of ground-glass opacities on computed tomography of the chest. Cessation of nitrofurantoin therapy leads to improvement and suffices in the management of some patients, although corticosteroid therapy may be helpful in those more severely affected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212142     DOI: 10.4065/80.10.1298

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  18 in total

1.  Nitrofurantoin-induced pulmonary reaction involving respiratory symptoms: case report.

Authors:  Zahra Kanji; Victoria C H Su; Raj Mainra
Journal:  Can J Hosp Pharm       Date:  2011-09

2.  Chest pain, dyspnea, and cough.

Authors:  Val E Ginzburg
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

3.  Nitrofurantoin-induced interstitial pneumonitis: albeit rare, should not be missed.

Authors:  Haamid Syed; Ghassan Bachuwa; Sunil Upadhaya; Firas Abed
Journal:  BMJ Case Rep       Date:  2016-02-24

4.  Nitrofurantoin-associated bronchiolitis obliterans organizing pneumonia: report of a case.

Authors:  Mark E Fenton; Rani Kanthan; Donald W Cockcroft
Journal:  Can Respir J       Date:  2008-09       Impact factor: 2.409

5.  Nitrofurantoin related pulmonary disease: a clinical reminder.

Authors:  Timothy David Reynolds; Jose Thomas
Journal:  BMJ Case Rep       Date:  2013-05-31

6.  Drug induced interstitial lung disease.

Authors:  Martin Schwaiblmair; Werner Behr; Thomas Haeckel; Bruno Märkl; Wolfgang Foerg; Thomas Berghaus
Journal:  Open Respir Med J       Date:  2012-07-27

7.  Relapsing nitrofurantoin-induced pneumonitis.

Authors:  Richard D Turner; Chris M Barber
Journal:  Respir Med Case Rep       Date:  2011-12-12

8.  Unrecognized Interstitial Lung Disease as a Result of Chronic Nitrofurantoin Use.

Authors:  Kerry Anne Rambaran; Charles F Seifert
Journal:  Drug Saf Case Rep       Date:  2016-12

9.  Reversible interstitial lung disease with prolonged use of nitrofurantoin: Do the benefits outweigh the risks?

Authors:  Akashdeep Singh; Parminder Singh; U S Sidhu
Journal:  Lung India       Date:  2013-07

10.  Nitrofurantoin induced interstitial lung disease.

Authors:  G D Naidu; P Deepthi; K Raja Karthik; U Das; G Swarnalatha; T Gangadhar
Journal:  Indian J Nephrol       Date:  2014-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.